N-octadecyloctadecan-1-amine;hydrobromide | 103229-03-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-octadecyloctadecan-1-amine;hydrobromide
• CAS: 103229-03-4
• 化学式: C36H76BrN
• 分子量: 602.9
• InChiKey: ZLDPNFYTUDQDMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.68
• 重原子数：
  38
• 可旋转键数：
  34
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为试剂：
  描述：

  双十八烷基胺 、 对氰基溴化苄 在 N-octadecyloctadecan-1-amine;hydrobromide 作用下， 以 氯仿 为溶剂， 反应 24.0h， 以to give 1-(dioctadecylamino)methyl-4-cyanobenzene (15.5 g., 97.5% yield)的产率得到1-(dioctadecylamino)methyl-4-cyanobenzene
  参考文献：
  名称：

  Xylene-diamines as antiviral agents

  摘要：

  化合物的公式为##STR1##或其非毒性酸加成盐，其中R.sub.1是由1到20个碳原子组成的烷基；R.sub.2是由12到20个碳原子组成的烷基；R.sub.3选择自氢和由2到8个碳原子组成的羟基烷基；R.sub.4选择自氢，由1到8个碳原子组成的烷基和由2到8个碳原子组成的羟基烷基，这些化合物对于在脊椎动物中抗击病毒感染是有用的。

  公开号：

  US04034040A1

文献信息

• Additives and products including oligoesters
  申请人：——

  公开号：US20030199593A1

  公开（公告）日：2003-10-23

  The present invention relates to oligoesters and their use or the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care products such as shampoos and conditioners. These oligoesters are particularly useful for the creation of multi-purpose additives that can impart conditioning, long substantivity and/or UV protection. Individual oligoesters and oligoester mixtures are described.

  本发明涉及寡酯及其用途或添加剂的制备。含有寡酯的添加剂和/或寡酯本身可用于配制药物制剂、化妆品或个人护理产品，如洗发水和护发素。这些寡酯对于制备能够赋予调理、长效性和/或紫外线保护的多功能添加剂特别有用。描述了单独的寡酯和寡酯混合物。
• [EN] COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR ADMINISTRATION OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2020069353A1

  公开（公告）日：2020-04-02

  The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了新的Sunitinib、Brinzolamide和Dorzolamide的前药，以及用于治疗医学疾病的组合物，例如青光眼、与眼内压增高有关的疾病或异常（TOP）、需要神经保护的疾病、年龄相关性黄斑变性或糖尿病视网膜病变。
• TARGETED NANOPREPARATION OF MANNOSE, AND PREPARATION THEREFOR AND APPLICATION THEREOF
  申请人：CHENGDU RIBOCURE PHARMATECH COMPANY LIMITED

  公开号：US20210196832A1

  公开（公告）日：2021-07-01

  The present invention relates to the field of pharmaceutical preparations, in particular, to a mannose modified targeting nano-preparations, a composition for preparing nano-preparations, a targeting element, a targeting vector, a prepared targeting drug and a preparation method and the application thereof. The described nano-preparations with targeting function is composed of the targeting ligand mannose and its derivatives, nano-preparations and main drug components, and the described targeting material is linked with the spacer material, and then linked with the nano-preparations material to prepare the nano-preparations. The targeting nano-preparations in the present invention has good targetability of mannose receptor, can effectively bond with mannose receptor on target cell. Moreover, the preparation method has universality, can be used for synthesizing a variety of targeting nano-preparations, and is conducive to purification and characterization.

  本发明涉及制药制剂领域，具体地说，涉及一种甘露糖修饰靶向纳米制剂，用于制备纳米制剂的组合物，靶向元素，靶向载体，制备的靶向药物以及其制备方法和应用。所述具有靶向功能的纳米制剂由靶向配体甘露糖及其衍生物、纳米制剂和主要药物成分组成，所述靶向材料与间隔材料连接，然后与纳米制剂材料连接以制备纳米制剂。本发明的靶向纳米制剂具有良好的甘露糖受体靶向性，能够有效地与靶细胞上的甘露糖受体结合。此外，制备方法具有普适性，可用于合成各种靶向纳米制剂，并有利于纯化和表征。
• [EN] SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE<br/>[FR] RADIOFLUORATION SPÉCIFIQUE DE SITE DE PEPTIDES AVEC DE L'ACIDE 8-[18F]FLUOROOCTANOÏQUE CATALYSÉE PAR UNE ACIDE LIPOÏQUE LIGASE
  申请人：UNIV CALIFORNIA

  公开号：WO2017095806A1

  公开（公告）日：2017-06-08

  New methodologies for site-specifically radiolabeling proteins with the PET isotope [18F] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overcomes many of the limitations encountered to date with purely chemical approaches. The bacterial enzyme lipoic acid ligase was used to conjugate [18F]-fluorooctanoic acid to both a small peptide and a Fab antibody fragment. Labeling was site-specific and highly efficient under mild aqueous conditions using small amounts of peptide/protein (1-10 nmol). The labeled construct retained full epitope binding affinity and was stable in mouse serum. Using an optimized reaction scheme, mCi quantities of [18F]-Fab were generated, an amount sufficient for human imaging.

  用PET同位素[18F]对蛋白质进行特异性标记的新方法对于在临床前和临床环境中生成高质量放射示踪剂是必需的。酶促放氟反应克服了迄今为止纯化学方法所遇到的许多限制。细菌酶硫辛酸连接酶被用于将[18F]-氟辛酸与小肽和Fab抗体片段结合。在温和水性条件下，使用少量的肽/蛋白质（1-10 nmol），标记是特异性的且高效的。标记的构建物保留了完整的抗原结合亲和力，并在小鼠血清中稳定。使用优化的反应方案，产生了足够进行人体成像的mCi数量的[18F]-Fab。
• Imidazoline quats
  申请人：Croda, Inc.

  公开号：US20040220062A1

  公开（公告）日：2004-11-04

  Mixture of dialkyl imidazoline quats with specified substitution content are provided. In one embodiment, at least a portion of the mixture includes at least one dialkyl imidazoline quat having at least one C 16 -C 30 alkyl group; the C 16-30 substitution content of the mixture being from about 10% to about 95% with respect to C 10+ reference substitution range. Methods of making imidazoline quats and quat mixtures, personal care and cosmetic products and formulations that contain the imidazoline quats and quat mixtures, methods of making such personal care and cosmetic products and formulations, and methods of using the such imidazoline quats, quat mixtures, and personal care and cosmetic products and formulations are also provided. Various embodiments are disclosed.

  提供具有指定取代含量的二烷基咪唑啉季铵盐混合物。在一个实施例中，至少部分混合物包括至少一种具有至少一个C16-C30烷基基团的二烷基咪唑啉季铵盐；混合物的C16-C30取代含量相对于C10+参考取代范围约为10%至95%。还提供制备咪唑啉季铵盐和季铵盐混合物的方法，包含咪唑啉季铵盐和季铵盐混合物的个人护理和化妆品产品和配方，制备这种个人护理和化妆品产品和配方的方法，以及使用这种咪唑啉季铵盐、季铵盐混合物、个人护理和化妆品产品和配方的方法。还披露了各种实施例。